原发性房角关闭性疾病患者单纯超声乳化与超声乳化联合房角分离术的疗效:一项随机临床试验
该多中心随机临床试验纳入78例伴有白内障的原发性房角关闭性疾病(PACD)且周边虹膜前粘连≥90°的患者,比较单纯超声乳化联合人工晶状体植入(PEI)与PEI联合房角分离术(GSL)的1年眼压结局;结果显示两组1年手术成功率无显著差异(PEI组52.5% vs PEI-GSL组57.9%,P=0.63),未能证明PEI-GSL较PEI额外降低眼压。
要点
- 在伴有白内障的PACD患者中,PEI-GSL组1年手术成功率57.9%,PEI组52.5%,差异无统计学意义(P=0.63)。
- 两组术后并发症发生率相近:PEI组3例(7.5%),PEI-GSL组3例(7.9%)。
- 两组1年用药数量均较基线下降(P均<0.001),组间变化差异无统计学意义(P=0.06)。
核心结论
- 该随机临床试验未能证明在PACD患者中PEI-GSL较单纯PEI额外降低眼压。
研究设计与样本
- 多中心随机临床试验,于2011年9月29日至2015年3月16日开展,数据分析于2015年4月1日至2019年3月4日进行。
- 纳入原发性房角关闭或原发性闭角型青光眼且周边虹膜前粘连≥90°并伴有白内障的患者,随机接受单纯PEI或PEI-GSL,随访1年,采用意向性分析。
- 共分析78例患者(78眼),其中中国患者37例(47.4%),女性54例(69.2%),平均(SD)年龄67.7(8.9)岁,基线平均偏差(SD)-13.5 dB(9.4 dB)。
- PEI组40例,PEI-GSL组38例。
主要发现
- 基线平均(SD)眼压:PEI组22.3(8.5)mm Hg,PEI-GSL组22.9(5.3)mm Hg。
- 1年平均眼压:PEI组14.3(5.0)mm Hg,PEI-GSL组15.9(4.5)mm Hg。
- 1年手术成功(眼压≤21 mm Hg且未使用降眼压药物且眼压较基线下降≥20%)率:PEI组21例(52.5%) vs PEI-GSL组22例(57.9%),平均差异5.4%(95%CI -18.0%至28.2%;P=0.63)。
- 达到手术成功的患眼中,1年平均眼压:PEI组12.5(2.7)mm Hg(范围7.0-19.0),PEI-GSL组13.6(2.4)mm Hg(范围9.0-18.0)。
- 基线至1年用药数量:PEI组由平均2.2(0.8)降至0.5(0.9)(P<0.001),PEI-GSL组由1.9(0.9)降至0.6(1.2)(P<0.001),平均变化差异0.4%(95%CI -0.02%至0.9%;P=0.06)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effectiveness of intraocular pressure (IOP) lowering phacoemulsification combined with goniosynechialysis (GSL) compared with phacoemulsification without GSL remains unknown. OBJECTIVE: To compare the IOP outcome after 1 year in patients with synechial primary angle-closure disease (PACD) and cataract who underwent phacoemulsification with intraocular lens implantation (PEI) alone compared with PEI with GSL (PEI-GSL). DESIGN, SETTING, AND PARTICIPANTS: A multicenter randomized clinical trial was conducted from September 29, 2011, to March 16, 2015; data analysis was performed from April 1, 2015, to March 4, 2019. Patients with PACD, defined as primary angle closure or primary angle-closure glaucoma, and at least 90° peripheral anterior synechiae (PAS) with cataract were included. Patients were randomized to undergo PEI alone or PEI-GSL. Patients were followed up for 1 year with standardized evaluations. Intention-to-treat analysis was performed. INTERVENTIONS: Phacoemulsification with intraocular lens implantation alone or with GSL. MAIN OUTCOMES AND MEASURES: Successful control of IOP at 12 months, defined as IOP 21 mm Hg or lower without use of topical IOP-lowering medications and a decrease in IOP of 20% or more from baseline IOP. RESULTS: Data from 78 patients (78 eyes) were analyzed. Of these, 37 patients were Chinese (47.4%) and 54 were women (69.2%); mean (SD) age was 67.7 (8.9) years. Mean deviation (SD) at baseline was -13.5 dB (9.4 dB). Forty patients were randomized to the PEI group and 38 to the PEI-GSL group. The mean (SD) IOP at baseline was 22.3 (8.5) mm Hg for the PEI group and 22.9 (5.3) mm Hg for the PEI-GSL group. At 1 year, the mean IOP was 14.3 (5.0) mm Hg for the PEI group and 15.9 (4.5) mm Hg for the PEI-GSL group. Successful control at 1 year occurred in 21 patients (52.5%) in the PEI group and 22 patients (57.9%) in the PEI-GSL group (mean difference, 5.4%; 95% CI, -18.0% to 28.2%; P = .63). In eyes that achieved successful control, mean IOP at 1 year was 12.5 (2.7) mm Hg (range, 7.0-19.0) for the PEI group and 13.6 (2.4) mm Hg (range, 9.0-18.0) for the PEI-GSL group. The number of medications at baseline and 1 year decreased from a mean of 2.2 (0.8) to 0.5 (0.9) in the PEI group and 1.9 (0.9) to 0.6 (1.2) in the PEI-GSL group (P < .001 for each), with a mean change difference of 0.4% (95% CI, -0.02% to 0.9%; P = .06). There were 3 postoperative complications (7.5%) in the PEI group and 3 (7.9%) in the PEI-GSL group. These included IOP spike (IOP≥30 mm Hg) (n = 3), excessive anterior chamber inflammation (n = 1), and posterior capsule opacification (n = 2). CONCLUSIONS AND RELEVANCE: This randomized clinical trial was unable to show that PEI-GSL added additional IOP lowering compared with PEI alone in patients with PACD. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02376725.
引用
- Husain R, Do T, Lai J, et al. Efficacy of Phacoemulsification Alone vs Phacoemulsification With Goniosynechialysis in Patients With Primary Angle-Closure Disease: A Randomized Clinical Trial. JAMA Ophthalmol. 2019. PMID: 31294768. doi:10.1001/jamaophthalmol.2019.2493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。